• Bloomberg

  • SHARE

Takeda Pharmaceutical Co.’s $2.37 billion settlement of thousands of lawsuits over its Actos diabetes medicine did not attract enough takers ahead of a deadline, raising doubts about whether the deal will survive.

Asia’s largest drugmaker is obligated to fund the deal after 95 percent of those with claims join it. By Wednesday’s deadline, about 75 percent had signed up, said Andy Birchfield, a lawyer overseeing cases consolidated in federal court in Louisiana. Claimants now have until Sept. 11.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)